Chemical compounds
US-2018111931-A1 · Apr 26, 2018 · US
Chemical compounds
US10149839B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10149839-B2 |
| Application number | US-201715657395-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 24, 2017 |
| Priority date | Jul 25, 2016 |
| Publication date | Dec 11, 2018 |
| Grant date | Dec 11, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The specification relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound, or a pharmaceutically acceptable salt thereof, wherein the compound is N-(2-((5-((1R,3R)-2-(2,2-difluoroethyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-4-methoxypyridin-2-yl)oxy)ethyl)-3-fluoropropan-1-amine, which compound has the following structure: 2. A pharmaceutical composition, which comprises the compound according to claim 1 , or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically-acceptable excipient. 3. A compound, wherein the compound is N-(2-((5-(1R,3R)-2-(2,2-difluoroethyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-4-methoxypyridin-2-yl)oxy)ethyl)-3-fluoropropan-1-amine. 4. A pharmaceutical composition, which comprises the compound according to claim 3 , in association with a pharmaceutically-acceptable excipient. 5. A pharmaceutically acceptable salt of N-(2-((5-((1R,3R)-2-(2,2-difluoroethyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-4-methoxypyridin-2-yl)oxy)ethyl)-3-fluoropropan-1-amine. 6. A pharmaceutical composition, which comprises the salt according to claim 5 , in association with a pharmaceutically-acceptable excipient. 7. A pharmaceutically acceptable salt, wherein the pharmaceutically acceptable salt is the 2-methoxybenzoate salt of N-(2-((5-((1R,3R)-2-(2,2-difluoroethyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-4-methoxypyridin-2-yl)oxy)ethyl)-3-fluoropropan-1-amine. 8. A pharmaceutical composition, which comprises the salt according to claim 7 , in association with a pharmaceutically-acceptable excipient.
Assignees
Inventors
Classifications
having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53}) · CPC title
by using a differential method · CPC title
not condensed and containing further heterocyclic rings · CPC title
Antineoplastic agents · CPC title
- A61K31/437Primary
the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10149839B2 cover?
- The specification relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
- Who is the assignee on this patent?
- Astrazeneca Ab
- What technology area does this patent fall under?
- Primary CPC classification A61K31/437. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).